Page last updated: 2024-11-05

2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7534
CHEMBL ID1618660
CHEBI ID94371
SCHEMBL ID132347

Synonyms (45)

Synonym
100-91-4
BRD-A37942872-003-03-2
PRESTWICK3_000794
benzeneacetic acid, .alpha.-hydroxy-, 1,2,2,6-tetramethyl-4-piperidinyl ester
eucatropine
BPBIO1_001022
NCGC00179372-01
PRESTWICK2_000794
BSPBIO_000928
SPBIO_002867
PRESTWICK0_000794
PRESTWICK1_000794
(1,2,2,6-tetramethylpiperidin-4-yl) 2-hydroxy-2-phenylacetate
L000976
eucatropinum
eucatropinum [inn-latin]
4spj105w8e ,
einecs 202-900-0
eucatropine [inn:ban]
eucatropina
eucatropina [inn-spanish]
unii-4spj105w8e
nsc_7534
bdbm82377
cas_100-91-4
SCHEMBL132347
eucatropin
mandelic acid, 1,2,2,6-tetramethyl-4-piperidyl ester
euphthalmine
4-hydroxy-1,2,2,6-tetramethylpiperidine mandelate
eucatropine dl-form [mi]
eucatropine [inn]
DTXSID1048465
eucatropine dl-form
CHEMBL1618660
1,2,2,6-tetramethyl-4-piperidinyl hydroxy(phenyl)acetate #
1,2,2,6-tetramethyl-4-piperidyl mandelate
QSAVEGSLJISCDF-UHFFFAOYSA-N
CHEBI:94371
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester
1,2,2,6-tetramethylpiperidin-4-yl 2-hydroxy-2-phenylacetate
FT-0712100
Q27166212
CS-0064980
HY-117284
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1623674Half life in mouse plasma2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1246315Half life in human plasma2015European journal of medicinal chemistry, Sep-18, Volume: 102(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1449541Metabolic stability in human blood assessed as compound remaining at 2 uM after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1585790Metabolic stability in CD-1 mouse plasma assessed as parent compound remaining at 3 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
AID1585789Metabolic stability in human plasma assessed as parent compound remaining at 3 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
AID1851937Stability in human plasma assessed as compound remaining measured after 2 hrs2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1604717Stability in human plasma assessed as parent compound remaining level at 5 uM at 37 degC measured at 240 mins by LC-MS analysis2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration.
AID1604715Stability in human plasma assessed as elimination rate at 5 uM at 37 degC measured up to 250 mins by LC-MS analysis2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration.
AID1604716Stability in human plasma assessed as half life at 5 uM at 37 degC measured up to 250 mins by LC-MS analysis2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration.
AID1246316Half life in mouse plasma2015European journal of medicinal chemistry, Sep-18, Volume: 102(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1623675Half life in human plasma2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1851938Stability in mouse plasma assessed as compound remaining measured after 2 hrs2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]